Composition of Certain Financial Statement Captions |
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands) |
June 30, 2020 |
|
December 31, 2019 |
Accounts receivable, net: |
|
|
|
Accounts receivable |
$ |
215,925 |
|
|
$ |
136,551 |
|
Less: allowance for credit losses |
(1,573) |
|
|
(1,934) |
|
|
$ |
214,352 |
|
|
$ |
134,617 |
|
Inventories, net: |
|
|
|
Consumable supplies |
$ |
41,298 |
|
|
$ |
23,005 |
|
Finished products |
24,259 |
|
|
25,142 |
|
Work in-process |
4,711 |
|
|
3,238 |
|
Raw materials |
5,826 |
|
|
4,586 |
|
Less: inventory reserve |
(3,129) |
|
|
(2,537) |
|
|
$ |
72,965 |
|
|
$ |
53,434 |
|
Other current assets and prepaid expenses: |
|
|
|
Taxes recoverable |
$ |
12,135 |
|
|
$ |
19,808 |
|
Prepaid expenses |
12,999 |
|
|
8,147 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Prepaid insurance |
6,274 |
|
|
3,486 |
|
Other receivables |
661 |
|
|
3,262 |
|
Other |
19,056 |
|
|
15,839 |
|
|
$ |
51,125 |
|
|
$ |
50,542 |
|
Intangible assets, net: |
|
|
|
Customer relationships |
$ |
445,144 |
|
|
$ |
445,408 |
|
Technologies |
296,251 |
|
|
296,246 |
|
Trade names |
49,771 |
|
|
49,786 |
|
|
|
|
|
Covenants not to compete |
16,318 |
|
|
16,318 |
|
Licenses |
5,766 |
|
|
5,766 |
|
Product registrations |
7,109 |
|
|
7,578 |
|
Other |
6,100 |
|
|
6,094 |
|
Less: accumulated amortization |
(327,334) |
|
|
(298,234) |
|
|
$ |
499,125 |
|
|
$ |
528,962 |
|
Accrued expenses: |
|
|
|
Inventory received but not invoiced |
$ |
49,005 |
|
|
$ |
13,751 |
|
Commitments and Contingencies |
38,668 |
|
|
38,635 |
|
Employee benefits |
34,086 |
|
|
33,671 |
|
Contract liabilities |
16,570 |
|
|
19,196 |
|
Clinical trials |
6,079 |
|
|
8,122 |
|
|
|
|
|
Contingent consideration |
2,375 |
|
|
2,375 |
|
Finance leases short-term |
2,435 |
|
|
2,743 |
|
|
|
|
|
Professional fees |
4,009 |
|
|
1,333 |
|
|
|
|
|
|
|
|
|
Other |
56,884 |
|
|
45,099 |
|
|
$ |
210,111 |
|
|
$ |
164,925 |
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands) |
June 30, 2020 |
|
December 31, 2019 |
|
|
|
|
Other long-term liabilities: |
|
|
|
|
|
|
|
Line of credit |
$ |
51,489 |
|
|
$ |
44,749 |
|
Contingent consideration |
7,559 |
|
|
7,308 |
|
|
|
|
|
Mortgages and other debts payable |
4,201 |
|
|
3,906 |
|
Finance leases long-term |
2,960 |
|
|
4,046 |
|
Contract liabilities |
1,170 |
|
|
2,571 |
|
Other |
24,274 |
|
|
25,224 |
|
|
$ |
91,653 |
|
|
$ |
87,804 |
|
|
Changes in Goodwill |
The following table summarizes the changes in Goodwill by reporting unit during the six months ended June 30, 2020.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2020 |
|
|
|
|
|
|
(In thousands) |
Balance at January 1 |
|
|
|
Foreign exchange and other |
|
Balance at June 30th |
Pharmaceuticals |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rayaldee |
$ |
85,605 |
|
|
|
|
$ |
100 |
|
|
$ |
85,705 |
|
|
|
|
|
|
|
|
|
OPKO Chile |
4,348 |
|
|
|
|
(450) |
|
|
3,898 |
|
OPKO Biologics |
139,784 |
|
|
|
|
— |
|
|
139,784 |
|
OPKO Health Europe |
7,394 |
|
|
|
|
9 |
|
|
7,403 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diagnostics |
|
|
|
|
|
|
|
BioReference |
434,809 |
|
|
|
|
— |
|
|
434,809 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
671,940 |
|
|
|
|
$ |
(341) |
|
|
$ |
671,599 |
|
|